UC San Francisco and Quest Diagnostics launch collaboration to advance the field of precision medicine

PUBLIC RELEASE DATE:

9-Jan-2014

Contact: Kristen Bole kristen.bole@ucsf.edu 415-502-6397 University of California - San Francisco

MADISON, N.J. and SAN FRANCISCO, CA, January 9, 2014 Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and the University of California, San Francisco (UCSF), the nation's leading university focused exclusively on health, have formed a collaboration to accelerate the translation of biomedical research into advanced diagnostics in the field of precision medicine, for improved patient care, treatment and outcomes. Initial clinical areas of focus include autism, oncology, neurology and women's health.

The collaboration, which combines the research discoveries and capabilities of UCSF with the national testing database and technical and clinical development capability of Quest Diagnostics, has an overarching aim of enabling holistic and integrated diagnostic solutions that close gaps in care or enable new clinical value.

Under the terms of the agreement, scientists will jointly research, develop and validate diagnostic innovations to solve specific clinical problems and provide actionable information to improve patient care. The organizations will focus on diagnostics to advance precision medicine, an emerging field of medical science that aims to integrate the most informative data from molecular, clinical, population and other research to create predictive, preventive and precise medical solutions for patients. Quest Diagnostics would independently develop and validate any lab-developed tests for clinical use that emerge from the collaboration's research.

Researchers will utilize laboratory-based diagnostics, imaging procedures and population analysis based on Quest's national Health Trends database, the largest private clinical database in the U.S., based on more than 1.5 billion patient encounters, to advance precision medicine.

The alliance is the first master agreement that UCSF's Office of Innovation, Technology and Alliances has signed with a clinical laboratory testing company and augments the university's efforts to translate laboratory research into new therapies. The broad agreement lays the groundwork for multiple projects between the two organizations.

"Advances in technology and science have identified many promising opportunities to improve outcomes through insights revealed by novel diagnostic solutions, yet fulfilling the full potential of these opportunities often hinges on translational clinical studies which validate their value," said Jay Wohlgemuth, M.D., senior vice president, Science and Innovation, Quest Diagnostics. "This unique collaboration between UCSF and Quest brings together the finest researchers and clinicians in the country to accelerate the development of a 'product pipeline' of scientific discoveries as clinically valuable diagnostic solutions that enable precision medicine for improved outcomes."

The collaboration is launching with two specific projects already underway. One project involves Quest's national database of molecular testing data to facilitate participation in research and development efforts related to genetic variations of autism, based on Quest's CGH microarray ClariSure technology, which can help identify genetic mutations associated with autism and other developmental disorders. While there currently is no treatment for autism, a test that aids its diagnosis could help identify individuals who might be appropriate candidates for research studies that could lead to future therapies.

More:

UC San Francisco and Quest Diagnostics launch collaboration to advance the field of precision medicine

Molecular engines star in new model of DNA repair

PUBLIC RELEASE DATE:

8-Jan-2014

Contact: Lisa Greiner Lisa.Greiner@nyumc.org 212-404-3532 NYU Langone Medical Center / New York University School of Medicine

Our health depends in large part upon the ability of specialized enzymes to find and repair the constant barrage of DNA damage brought on by ultraviolet light radiation and other sources. In a new study NYU School of Medicine researchers reveal how an enzyme called RNA polymerase patrols the genome for DNA damage and helps recruit partners to repair it. The result: fewer mutations and consequently less cancer and other kinds of disease.

The study, led by Evgeny Nudler, PhD, a Howard Hughes Medical Investigator and the Julie Wilson Anderson Professor of Biochemistry at NYU Langone Medical Center, is being published online in the January 8 issue of Nature.

Scientists have long known that RNA polymerase slides along the telltale tracks of double-stranded DNA and uses that template to create a growing chain of RNA molecules. This RNA chain, in turn, contains all of the information needed to construct cellular proteins. The enzyme, however, can stall as it patrols the tracks and encounters significant DNA damage. Even worse, it can become lodged over the damaged site, preventing any repair specialists from reaching it.

In the new study, the NYU School of Medicine researchers reveal how another enzyme called UvrD helicase acts like a train engine to pull the RNA polymerase backwards and expose the broken DNA so a repair crew can get to work.

The finding has major implications for a patching mechanism that is widely shared by organisms ranging from bacteria to humans, says Dr. Nudler. "Better repair means fewer mutations, which also means slower aging, less cancer and many other pathologies," he says.

Although the research, conducted in Escherichia coli bacteria, focused on one type of DNA repair, Dr. Nudler says the evidence suggests that other cellular repair pathways might use the same mechanism to recognize and then resolve the damage. Failure to do so can lead to profound consequences: inherited defects in the gene that encodes the human analog of UvrD, a protein known as XPB, have been linked to a range of devastating disorders.

In a condition known as xeroderma pigmentosum, for example, the faulty DNA repair system cannot fix damage caused by ultraviolet radiation. Consequently, any exposure to sunlight can cause serious skin and eye damage and greatly elevate the risk of skin cancer Similarly, children born with Cockayne syndrome age prematurely and are often short in stature due to inadequate DNA repair. Those with a third related condition called trichothiodystrophy have brittle hair, recurrent infections and delayed development.

Read the original here:

Molecular engines star in new model of DNA repair

When germs attack: A lens into the molecular dance

PUBLIC RELEASE DATE:

7-Jan-2014

Contact: Vanessa McMains vmcmain1@jhmi.edu 410-502-9410 Johns Hopkins Medicine

Researchers at Johns Hopkins have zoomed in on what is going on at the molecular level when the body recognizes and defends against an attack of pathogens, and the findings, they say, could influence how drugs are developed to treat autoimmune diseases.

The focus of the research is a pathogen "sensor" known as human IFN inducible protein-16 or IFI16, one of the body's key responders to viruses and bacteria, including herpes, HIV, listeria and salmonella. When IFI16 goes awry, it can prod the immune system to attack its own cells, triggering autoimmune disorders such as lupus and Sjgren syndrome (in which the glands that produce tears and saliva are destroyed). By figuring out how IFI16 operates, biophysicist Jungsan "Jay" Sohn, Ph.D., and his team say they have set the stage for finding ways to stop or limit the damage.

For the study, described online at the Proceedings of the National Academy of Science Early Edition in December, the Hopkins team used high-powered microscopy to show that these sensor proteins of the human immune system assemble into strands to signal infection. This strand-forming appears in other pathogen sensors, suggesting that this may be a common host defense mechanism.

"By understanding how IFI16 works at this fine molecular level, we may be able to boost this activity to build up immunity or taper down this activity to correct autoimmune disorders," says Sohn, an assistant professor of biophysics and biophysical chemistry.

Sohn and his research team first generated genetically engineered IFI16 from bacteria and exposed it to synthetic DNA sequences of varying lengths to see how the protein might react to "foreign," pathogenic DNA. They then observed the IFI16 and DNA interact via electron microscopy. What they saw was surprising.

The team expected that IFI16, like other pathogen sensors, would react to foreign DNA if it is long enough to accommodate just one IFI16 molecule. But IFI16 didn't react strongly until the synthetic DNA fragments exceeded 60 base pairs in length, which can accommodate about four IFI16 molecules. It was as if a light went on when the "invading" DNA reached 70 to 100 base pairs, Sohn says. "We call that switch-like behavior."

IFI16's preference for long DNA strands explains a longstanding mystery, according to Sohn. Researchers, he explains, have wondered how our bodies' immune systems mostly avoid "friendly fire," or being sent into overdrive and attacking themselves. The new experiments suggest that the length of DNA could be the key: Our DNA is packaged such that there are only short exposed fragments, and IFI16 won't activate in the presence of short DNA, but will in the presence of pathogenic DNA, which typically expose much longer strands.

Link:

When germs attack: A lens into the molecular dance

Molecular Diagnostics Role in Cancer Testing Analyzed in In-demand TriMark Report Published at MarketPublishers.com

London, UK (PRWEB) January 06, 2014

Nowadays, molecular diagnostics (MD) represents a promising area of research and medicine, which is witnessing tremendous technology advancements alongside the emergence of novel applications. The range of technologies associated with MD includes, amid others, gene expression profiling using microarrays, DNA probes, next-generation signal detection, first-generation amplification, fluorescent in-situ hybridization (FISH), second-generation microfluidics and biochips, and biosensors and molecular labels. These technologies are essential tools playing vital roles in the optimization of drug therapy, in the discovery of new therapeutic molecules for cancer as well as in the screening, classification and diagnosis of cancer patients. Presently, MD for cancer testing is deemed as the most lucrative area for innovations and growth.

The pool of MD industry players includes but is not limited to CombiMatrix Corporation, LabCorp, Rosetta Genomics, Biodesix, Nuvera Biosciences, Targeted Molecular Diagnostics, Exact Sciences Corporation, bioTheranostics, InterGenetics, Orion Genomics, Sequenom, SABiosciences Corporation, Cancer Genetics and Nuvera Biosciences.

In-demand research report Molecular Diagnostics in Cancer Testing drawn up by TriMark Publications LLC (TriMark) has been recently published by Market Publishers Ltd.

Report Details:

Title: Molecular Diagnostics in Cancer Testing Published: November, 2013 Pages: 232 Price: US$ 3,400.00 http://marketpublishers.com/report/in_vitro_diagnostics/molecular_diagnostics/molecular-diagnostics-in-cancer-testing.html

The research study presents a comprehensive analysis of the MD field with a particular focus on the MD tests for cancer. It uncovers valuable information on the size and growth prospects of the MD market in its cancer detection and therapy applications; provides a thorough examination of the major factors influencing the development of the overall market and its certain segments, and also discloses sales statistics. The report presents description of the actual market state along with insights into the historical evolution of the sector, pinpoints the top market opportunities, covers the regulative framework, offers a snapshot of the existing MD technologies used for cancer testing applications as well as presents a summary of the recent business activities in the field. The study delves into the competitive landscape, unveils valuable data on the key market participants, and also contains forecasts for the MD market development in the next 5 years.

Report Features & Benefits:

More insightful research reports by TriMark can be found at http://marketpublishers.com/members/trimark/info.html.

Excerpt from:

Molecular Diagnostics Role in Cancer Testing Analyzed in In-demand TriMark Report Published at MarketPublishers.com

Newly Discovered Molecular Targets May Treat Difficult Melanomas

January 1, 2014

redOrbit Staff & Wire Reports Your Universe Online

A recently-published study in the journal Clinical Cancer Research supported by the Stand Up To Cancer (SU2C) charitable foundation has identified new molecular targets which could potentially result in new remedies for difficult-to-treat melanomas.

A team of investigators, including Dr. Jeffrey A. Sosman of the Vanderbilt-Ingram Cancer Center and Dr. William Pao of the Vanderbilt University School of Medicine, found two novel BRAF fusions in skin cancers previously believed to lack molecular targets. Furthermore, they found that melanomas with these fusions might be sensitive to anticancer drugs known as MEK inhibitors.

BRAF genes provide instructions for the creation of a protein that transmits chemical signals from the outside of a cell to its nucleus. It is part of a class of genes known as oncogenes, and if these genes mutate they can cause cells to become cancerous, the US National Library of Medicine explained.

According to Dr. Sosman, approximately 35 percent of all melanomas are currently considered pan-negative, meaning that they lack any previously known driver mutations in the BRAF gene or other potential genetic triggers (including mutations in the NRAS, KIT, GNAQ, and GNA11 genes).

He said that he and his colleagues have been studying patients lacking these driver mutations, searching for potential treatment targets within their tumors. In some forms of cancer, two or more genes fuse erroneously, producing irregular proteins that can effectively serve as the drivers of their cancers.

Performing a sophisticated analysis called targeted next-generation sequencing, it appears that about 8 percent of pan-negative melanomas have BRAF fusions, Dr. Sosman explained in a statement. Our results are important because they obviously suggest that there probably are other, as yet unidentified, molecular changes that make these melanomas susceptible to drugs that are available right now.

Dr. Sosman and Dr. Pao analyzed a pan-negative melanoma sample from one of their patients, and found a fusion between two genes (PAPSS1 and BRAF) which they dubbed PAPSS1-BRAF. They then went on to study melanomas from 51 other patients, including 24 which were pan-negative. In those two-dozen pan-negative samples, they found a second novel BRAF fusion, which they called TRIM24-BRAF.

Following additional research, the doctors and their colleagues found that both of these newly-discovered BRAF fusions activated a pathway in the cancer cells known as the MAPK signaling pathway. They treated these cells with either a BRAF inhibitor (vemurafenib) or an MEK inhibitor (trametinib).

See original here:

Newly Discovered Molecular Targets May Treat Difficult Melanomas

Welcome to the Department of Biochemistry and Molecular Medicine

The Oak Park Research Center is a 40,000-square-foot research building (photo on Left) and home of the Department of Biochemistry & Molecular Medicine and the Center for Biophotonics. The Health Sciences District on the Davis campus is home to Tupper Hall (photo on Right), where many of the medical schools basic science departments are located; Carlson Medical Library; and the Genome (photo in middle) and Biomedical Sciences building where researchers are studying genes that influence human health and development.

Our Mission is to conduct world-class research in biochemistry and molecular medicine. To excel in undergraduate, graduate and medical education, and to serve the university through leadership in forums committed to graduate and professional school admissions and curriculum.

The research interests of the departmental faculty are focused in the fundamental molecular aspects of cell biology, gene expression, cancer biology, membrane biology, glycobiology, neurobiology, muscle physiology, human genetics, chemical and structural biology, molecular imaging and drug development. In addition to innovative research activities, faculty are involved in the teaching and training of medical and doctoral students.

At the Davis Campus, the department maintains laboratories at Tupper Hall, the Genome Building and in the Department of Chemistry. At the Sacramento Campus, the department maintains laboratories at the Oak Park Research Building, Research I and III Buildings, and the MIND Institute.

The departments primary research funding comes from the National Institutes of Health, National Science Foundation, Department of Defense, and a wide variety of Private agencies. .

Read this article:

Welcome to the Department of Biochemistry and Molecular Medicine

Molecular Medicine – Official Site

Published by theFeinstein Institute for Medical Research(New York),Molecular Medicinestrives to understand normal body functioning and disease pathogenesis at the molecular level, which may allow researchers and physician-scientists to use that knowledge in the design of specific molecular tools for disease diagnosis, treatment, prognosis, and prevention. Manuscripts submitted to the journal should maintain this focus and describe the implications for human disease, at a level approachable by the broad readership ofMolecular Medicine. Click here for moreregarding the editorial process.

View Molecular Medicine'sEditorial Board.

The 2012 Journal Citation Report (JCR), showing impact factors calculated from citations of articles published in 2011 and 2010, listsMolecular Medicinewith an impact factor of 4.469. JCR category rankings are as follows: Medicine, Research & Experimental 22/121, Cell Biology 57/184, Biochemistry & Molecular Biology 66/290.

Molecular Medicinepublishes work in the format of original research articles, review articles, editorials, commentaries, and letters to the editor covering emerging concepts in the interdisciplinary field of molecular medicine. Authors click here for more information.

Are you reviewing a manuscript for Molecular Medicine? Click here for a 'how-to' guide.

Go here to read the rest:

Molecular Medicine - Official Site

Molecular Medicine – Wake Forest School of Medicine

The Section of Molecular Medicine focuses on performing cutting-edge research in cellular and molecular mechanisms of human disease and supports graduate and postgraduate level educational programs within the Department of Internal Medicine.

A major goal of the section is to serve as a nidus for translational research by providing an environment where clinical and basic science faculty interact to make new discoveries and to educate future scientists.

The section consists of 6 primary faculty members who use cellular and molecular approaches to gain a better understanding of the basic mechanisms underlying several chronic human conditions including asthma, arthritis, inflammation, infection and aging.

A particular research focus is cell signaling and the regulation of gene expression. The research in the section is supported by grants from the NIH, from foundations including the American Federation for Aging Research, the Arthritis Foundation, and the American Heart Association, froman endowed professorship and from partnerships with industry.

The section also provides a center for laboratory research training and education in translational research for medical students, residents, and postdoctoral fellows including subspecialty fellows in the Department of Internal Medicine. A seminar series is held weekly in conjunction with the graduate program in Molecular Medicine.

Richard F. Loeser, Jr., MD The Dorothy Rhyne Kimbrell and Willard Duke Kimbrell Professor of Internal Medicine Head, Section of Molecular Medicine

Go here to see the original:

Molecular Medicine - Wake Forest School of Medicine

Graduate Program in Molecular Medicine: GPILS: University of …

The Graduate Program in Molecular Medicine at the University of Maryland Baltimore offers research and training opportunities with internationally-renowned scientists. Our Molecular Medicine Program is an interdisciplinary program of study leading to a Ph.D. degree. There are three different research tracks: Cancer Biology, Genome Biology and Molecular Physiology & Pharmacology. Each provides for a unique interdisciplinary research and graduate training experience that is ideally suited for developing scientists of the post-genomic era.

Faculty mentors in this graduate program are leaders in their respective research areas and reside in various departments and Organized Research Centers in the School of Medicine and Dental School, the Institute for Genomic Sciences (IGS), the Institute of Human Virology (IHV), the Marlene and Stewart Greenebaum Cancer Center, and the Center for Vascular and Inflammatory Diseases (CVID). The over 150 faculty in the Graduate Program in Molecular Medicine are internationally recognized for their research in biotechnology, cancer, cardiovascular and renal biology, functional genomics and genetics, membrane biology, muscle biology, neuroscience and neurotoxicology, reproduction and vascular biology.

Here is the original post:

Graduate Program in Molecular Medicine: GPILS: University of ...

Molecular Medicine

Enrollment is now open for online M.S. in Molecular Medicine courses. Selected first-year courses are now available online. They offer the same quality and accredited curricula as an on-campus course, but with a flexible schedule.

For more information: Contact, Kate Pelusi at kpelusi@drexelmed.edu.

The Master of Science in Molecular Medicine Program provides training in the academic, research and entrepreneurial aspects of the biomedical sciences with an emphasis on translational research in the development of therapeutics and vaccines.

Participation in the program will provide enhanced educational credentials through a flexible curriculum, with most classes offered in the early evening to maximize accessibility. Classes can be attended at any of three Drexel University College of Medicine locations: Center City and Queen Lane campuses in Philadelphia, and the Pennsylvania Biotechnology Center in nearby Doylestown. State-of-the-art videoconferencing provides real-time interactive learning at all three locations.

Online versions of selected first-year courses are now available.

In addition to broad geographic access, the curriculum provides flexibility in content and course load. Most students will complete the program in two years through completion of required courses and electives selected from two menus: research theory and laboratory research. The latter includes the option of either an intensive summer research internship in a biotechnology-based company or part-time research training in an academic research setting. Some students may opt to complete the program on a part-time basis, taking up to four years. In either sequence, no dissertation is required. Program directors and course faculty will work closely with each student to best achieve his or her specific goals.

The Master of Science in Molecular Medicine Program is designed to provide academic and practical biotechnological knowledge in translational research, particularly in the areas of molecular therapeutics and vaccine development.

The molecular medicine program is ideally suited for enhancing the scientific credentials of the following groups:

The molecular medicine program is designed to be convenient and flexible to accommodate students. It features:

Originally posted here:

Molecular Medicine

Department of Molecular Medicine

How signals are transmitted from receptors to biological effectors

How does the cell maintain a redox environment in the ER appropriate for oxidative protein folding

We study the excitatory glutamate activated receptor-channels in the vertebrate central nervous system

How Ras-related GTPases regulate basic cellular processes

To understand the biology and enzymology of protein palmitoylation

How bacterial signaling is controlling biofilm formation and pathogenicity

To understand the molecular and cellular events that direct the formation of vertebrate organs

We study the structure and function of nicotinic acetylcholine and glutamate receptors in signal transduction

To reveal the architecture and molecular mechanisms of membrane proteins that mediate extracellular signaling

The mission of the Department of Molecular Medicine is to make fundamental discoveries in basic research that will be relevant to and impact the biomedical community; educate and train graduate students, postdoctoral (Ph.D) and DVM fellows, and educate veterinary students in the basic biological concepts that underlie the development of treatment strategies.

See original here:

Department of Molecular Medicine

UCSD Department of Cellular and Molecular Medicine Homepage

The mission of the Department of Cellular and Molecular Medicine is to support and promote research and teaching in molecular cell biology in the School of Medicine at UCSD (University of California at San Diego). The Department was first established as an autonomous Division in 1990 and was departmentalized in 1999. It is one of only two basic science departments in the School of Medicine at UCSD (University of California at San Diego). It consists of 23 faculty, more than 100 postdoctoral scholars, ~50 graduate students and over 80 staff. The Department plays a major role in the teaching the medical student and graduate student curricula in molecular cell biology.Cell biology remains the central discipline for the postgenomic era. More than 50 years ago E. B. Wilson wrote, "The key to every biological problem must finally be sought in the cell." Nearly 150 years ago, Virchow in his famous book, Cellular Pathology wrote that "All diseases are reducible to active or passive disturbances in cells".

Today cell biology has become the central basic science discipline in Biomedical research and in medical practice. It bridges biochemistry and structural biology to clinical medicine. Modern day cell biologists have the unprecedented opportunity to understand basic cellular processes as well as their derangements in diseases in molecular termsoften referred to as Molecular Cell Biology and Molecular Medicine. Todays molecular cell biologists utilize information obtained from biochemistry, genetic, and molecular approaches as well as sophisticated morphological techniques such as deconvolution, confocal and video microscopy and electron microscopy to the study of basic problems in cell biology and molecular medicine. They also take advantage of insights gained from proteomics, genomics and bioinformatics analyses. With the mapping of the human genome, the challenge becomes to understand the role of individual proteins and genes in cell function and disease. Thus the challenging frontier for the postgenomic era is centered in modern molecular cell biology.

Graduate Studies at University of California at San Diego (UCSD) In the School of Medicine graduate training in cell biology is centered in the Biomedical Sciences Graduate Program where it constitutes one of the main areas of study. There are abundant opportunities within the department to investigate problems in modern molecular cell biology with investigators who are internationally recognized and working at the cutting edge of their discipline.

See more here:

UCSD Department of Cellular and Molecular Medicine Homepage

Cellular and Molecular Medicine, Department and PhD Graduate …

Welcome to the Department of Cellular and Molecular Medicine at the University of Arizona. Department faculty pursue excellence through teaching in the medical curriculum and graduate and undergraduate courses, through the pursuit of leading edge biomedical research, and through service to the University, local community and the nation.

Department faculty run active research programs in modern molecular and cellular biology which include areas of developmental biology, neuroscience, parasitology, immunology, cancer biology, and cellular structure and function. Our PhD graduate program attracts outstanding students from all parts of the US and the world. Graduate students from the interdisciplinary programs of Cancer Biology, Genetics, Molecular & Cellular Biology and Biochemistry, Neuroscience, and Physiological Sciences also receive training in CMM faculty laboratories.

The Department has an extensive seminar and student research seminar program with guest speakers from around the country and abroad. The Department provides a stimulating academic environment and we welcome you to explore the scope of these activities as you navigate through this website.

Read the original post:

Cellular and Molecular Medicine, Department and PhD Graduate ...

Molecular Medicine PhD Program – Graduate Training in …

The Lerner Research Institute at the Cleveland Clinic is home to the Molecular Medicine Ph.D. Program. The Cleveland Clinic is consistently rated among the top 4 U.S. Hospitals according to U.S. News & World Report and has been rated #1 in cardiac care for 18 consecutive years. Molecular Medicine Ph.D. students train in a state-of-the-art facility with over 700,000 square feet of research space and nearly 200 investigators.

The Molecular Medicine Ph.D. Program integrates medical knowledge into graduate training. The goal of this program is to train research scientists who are effective members of translational research teams working along side physicians. Our students are engaged in basic or applied research that is relevant to human health and can lead to new understanding of disease, clinical and diagnostic tools, medications, and therapies.

Molecular Medicine Ph.D. students have the opportunity to learn from faculty members at the Lerner Research Institute, the Cleveland Clinic Lerner College of Medicine and Case Western Reserve University. Our students focus on medically relevant research and train with research leaders in their fields of study as well as world-class clinicians.

We encourage all interested applicants to visit our FAQ's. If you have additional questions regarding the application process, please feel free to contact us!

View original post here:

Molecular Medicine PhD Program - Graduate Training in ...

Weatherall Institute of Molecular Medicine – Home

The mission of the MRC Weatherall Institute of Molecular Medicine (WIMM) is to undertake internationally competitive research into the processes underlying normal cell and molecular biology and to determine the mechanisms by which these processes are perturbed in inherited and acquired human diseases. It is also our mission to translate this research to improve human health. The WIMM is uniquely placed among biomedical institutes throughout the world in its pioneering vision of combining outstanding clinical research with excellent basic science. The WIMM Faculty currently includes an equal mixture of scientists and clinicians working together and in collaboration with the National Institute of Health Research, the NHS and commercial companies with the aim of improving the diagnosis and treatment of human diseases. The major topics of current research include haematology, immunology, stem cell biology, oncology and inherited human genetic diseases.

The Institute values communication with members of the broader scientific community and the general public and with the support of the MRC we have commissioned three short videos to explain our mission.

The following awards and a fellowship have recently been announced for WIMM researchers. Andrew Wilkie - Wellcome Trust Senior Investigator Award, Alison Simmons -Wellcome Trust New Investigator Award, Adam Mead - MRC Senior Clinical Fellowship, Rui Monteiro - BHF Intermediate Basic Science Research Fellowship, Marella de Bruijn, Catherine Porcher and Wojciech Niedzwiedz have all been awarded the title of University Research Lecturer in ...

News Archive

Grade 6: Salary 26,527 - 31,644 p.a. We are seeking a motivated and enthusiastic Research Assistant to work under the direct supervision of Dr Rui Monteiro. The post is funded by the British Heart Foundation until December 2017 with an immediate start. Dr Monteiro works in the Stem Cell Ontogeny Group of Professor Roger Patient within the Molecular Haematology Unit and is interested in understanding the cellular and molecular mechanisms ...

Continue reading here:

Weatherall Institute of Molecular Medicine - Home

The Molecular Medicine Tri Conference 2014

Plenary Keynote Presenters

Event-at-a-Glance

Submit Your Poster Today!

About the Tri-Conference

The 21st International Molecular Medicine Tri-Conference is the industrys Preeminent Event on Molecular Medicine, focusing on Drug Discovery, Genomics, Diagnostics and Information Technology. Spanning six days this year, the Tri-Conference includes an expanded program that includes 6 symposia, 20 short courses, and 15 conference programs. For the first time in over 10 years were bringing back a dedicated conference on sequencing. As many will recall this events infancy was heavily devoted to the Human Genome Project and we are excited to reintroduce sequencing to this event.

For over 20 years, Tri-Conference attendees gained insight and knowledge by attending, knowledge that they were able to take with them, and have an immediate impact on their research. Plan to attend this years Tri-Conference where you can be part of driving change and working towards shaping the future of medicine.

Why attend the Tri-Conference?

2013 Attendee Testimonials

Read the rest here:

The Molecular Medicine Tri Conference 2014